메뉴 건너뛰기




Volumn 3, Issue 4, 2008, Pages 521-529

Long-acting β2-agonists (LABA) in chronic obstructive pulmonary disease: Efficacy and safety

Author keywords

COPD; Efficacy; LABA; Safety

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID DERIVATIVE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; LONG ACTING DRUG; PLACEBO; SALMETEROL; THEOPHYLLINE; TIOTROPIUM BROMIDE; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; OXYGEN;

EID: 60249085056     PISSN: 11769106     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review
Times cited : (43)

References (71)
  • 1
    • 34247561439 scopus 로고    scopus 로고
    • Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease
    • Aaron SD, Vandemheen KL, Fergusson D, et al. 2007. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease. Ann Inter Med, 146:545-55.
    • (2007) Ann Inter Med , vol.146 , pp. 545-555
    • Aaron, S.D.1    Vandemheen, K.L.2    Fergusson, D.3
  • 2
    • 60249084256 scopus 로고
    • Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease
    • American Thoracic Society
    • American Thoracic Society. 1995. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 165:838-44.
    • (1995) Am J Respir Crit Care Med , vol.165 , pp. 838-844
  • 3
    • 60249099238 scopus 로고
    • Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilar on the rate of decline of FEV1. The Lung Health Study
    • Anthonisen NR, Connett JE, Kiley JP, et al. 1994. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilar on the rate of decline of FEV1. The Lung Health Study. JAMA, 23:241-49.
    • (1994) JAMA , vol.23 , pp. 241-249
    • Anthonisen, N.R.1    Connett, J.E.2    Kiley, J.P.3
  • 4
    • 13444250953 scopus 로고    scopus 로고
    • The effect of a smoking cessation intervention on 14.5-year mortality
    • Anthonisen NR, Skeans MA, Wise RA, et al. 2005. The effect of a smoking cessation intervention on 14.5-year mortality. Ann Inter Med, 142:233-39.
    • (2005) Ann Inter Med , vol.142 , pp. 233-239
    • Anthonisen, N.R.1    Skeans, M.A.2    Wise, R.A.3
  • 5
    • 2942735127 scopus 로고    scopus 로고
    • Small Airways in COPD
    • Barnes PJ. 2004. Small Airways in COPD. N Engl J Med, 350:2635-37.
    • (2004) N Engl J Med , vol.350 , pp. 2635-2637
    • Barnes, P.J.1
  • 6
    • 1542405163 scopus 로고    scopus 로고
    • National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care
    • British Thoracic Society
    • British Thoracic Society. 2004. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax, 59 (Suppl 1):1-232.
    • (2004) Thorax , vol.59 , Issue.SUPPL. 1 , pp. 1-232
  • 7
    • 33847172367 scopus 로고    scopus 로고
    • Salmeterol and fluticasone propionate and survival in chronic obstructive Pulmonary disease
    • Calverley PMA, Anderson JA, Celli BR, et al. 2007. Salmeterol and fluticasone propionate and survival in chronic obstructive Pulmonary disease. N Engl J Med, 356:775-89.
    • (2007) N Engl J Med , vol.356 , pp. 775-789
    • Calverley, P.M.A.1    Anderson, J.A.2    Celli, B.R.3
  • 8
    • 0347473812 scopus 로고    scopus 로고
    • Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease
    • Calverley PM, Boonsawat W, Cseke Z, et al. 2003a. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J, 22:912-19.
    • (2003) Eur Respir J , vol.22 , pp. 912-919
    • Calverley, P.M.1    Boonsawat, W.2    Cseke, Z.3
  • 9
    • 13444269557 scopus 로고    scopus 로고
    • Flow limitation and dynamic hyperinflation: Key concepts in modern respiratory physiology
    • Calverley PMA, Koulouris NG. 2005. Flow limitation and dynamic hyperinflation: key concepts in modern respiratory physiology. Eur Respir J, 25:186-99.
    • (2005) Eur Respir J , vol.25 , pp. 186-199
    • Calverley, P.M.A.1    Koulouris, N.G.2
  • 10
    • 0037425745 scopus 로고    scopus 로고
    • 2-agonists) study group, et al. 2003b. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomized controlled trial. Lancet, 361:449-56.
    • 2-agonists) study group, et al. 2003b. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomized controlled trial. Lancet, 361:449-56.
  • 11
    • 34447498332 scopus 로고    scopus 로고
    • A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD
    • Cazzola M, Andò F, Santus P, et al. 2007a. A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD. Pulm Pharmacol Ther, 20:556-61.
    • (2007) Pulm Pharmacol Ther , vol.20 , pp. 556-561
    • Cazzola, M.1    Andò, F.2    Santus, P.3
  • 12
    • 1942531936 scopus 로고    scopus 로고
    • 2-agonists and corticosteroids in stable COPD
    • 2-agonists and corticosteroids in stable COPD. Chest, 126:220-37.
    • (2004) Chest , vol.126 , pp. 220-237
    • Cazzola, M.1    Dahl, R.2
  • 13
    • 0345414503 scopus 로고    scopus 로고
    • The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD
    • Cazzola M, Di Marco F, Santus P, et al. 2004. The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD. Pulm Pharmacol Ther, 17:35-39.
    • (2004) Pulm Pharmacol Ther , vol.17 , pp. 35-39
    • Cazzola, M.1    Di Marco, F.2    Santus, P.3
  • 15
    • 0031810916 scopus 로고    scopus 로고
    • Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia
    • Cazzola M, Imperatore F, Salzillo A, et al. 1998. Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia. Chest, 114:411-15.
    • (1998) Chest , vol.114 , pp. 411-415
    • Cazzola, M.1    Imperatore, F.2    Salzillo, A.3
  • 17
    • 33751193695 scopus 로고    scopus 로고
    • The effective treatment of COPD: Anticholinergics and what else?
    • Cazzola M, Matera MG. 2006. The effective treatment of COPD: Anticholinergics and what else? Drug Discov Today: Ther Strat, 3:277-86.
    • (2006) Drug Discov Today: Ther Strat , vol.3 , pp. 277-286
    • Cazzola, M.1    Matera, M.G.2
  • 18
    • 33947723601 scopus 로고    scopus 로고
    • The additive effect of theophylline on a combination of formoterol and tiotropium in stable COPD: A pilot study
    • Cazzola M, Matera MG. 2007. The additive effect of theophylline on a combination of formoterol and tiotropium in stable COPD: A pilot study. Respir Med, 101:957-62.
    • (2007) Respir Med , vol.101 , pp. 957-962
    • Cazzola, M.1    Matera, M.G.2
  • 19
    • 23744435643 scopus 로고    scopus 로고
    • 2-adrenoceptor agonists. cardiovascular safety in patients with obstructive lung disease
    • 2-adrenoceptor agonists. cardiovascular safety in patients with obstructive lung disease. Drugs, 65:1595-610.
    • (2005) Drugs , vol.65 , pp. 1595-1610
    • Cazzola, M.1    Matera, M.G.2    Donner, C.F.3
  • 20
    • 30544443706 scopus 로고    scopus 로고
    • Effect of formoterol/ budesonide combination on arterial blood gases in patients with acute exacerbation of COPD
    • Cazzola M, Noschese P, De Michele F, et al. 2006. Effect of formoterol/ budesonide combination on arterial blood gases in patients with acute exacerbation of COPD. Respir Med, 100:212-17.
    • (2006) Respir Med , vol.100 , pp. 212-217
    • Cazzola, M.1    Noschese, P.2    De Michele, F.3
  • 21
    • 1442306237 scopus 로고    scopus 로고
    • The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease
    • Celli BR, Cole CG, Marin JM, et al. 2004. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med, 350:1005-12.
    • (2004) N Engl J Med , vol.350 , pp. 1005-1012
    • Celli, B.R.1    Cole, C.G.2    Marin, J.M.3
  • 22
    • 1842552109 scopus 로고    scopus 로고
    • Celli BR, MacNee W, ATS/ERS Task Force. 2004. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J, 23:932-46.
    • Celli BR, MacNee W, ATS/ERS Task Force. 2004. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J, 23:932-46.
  • 23
    • 28244446602 scopus 로고    scopus 로고
    • Budesonide and formoterol combination for the treatment of chronic obstructive pulmonary disease
    • Centanni S, Di Marco F. 2005. Budesonide and formoterol combination for the treatment of chronic obstructive pulmonary disease. Expert Opin Pharmacother, 6:2525-34.
    • (2005) Expert Opin Pharmacother , vol.6 , pp. 2525-2534
    • Centanni, S.1    Di Marco, F.2
  • 24
    • 33748902214 scopus 로고    scopus 로고
    • The connection between chronic obstructive pulmonary disease symptoms and hyperinflation and its impact on exercise and function
    • Cooper CB. 2006. The connection between chronic obstructive pulmonary disease symptoms and hyperinflation and its impact on exercise and function. Am J Med, 119:S21-S31.
    • (2006) Am J Med , vol.119
    • Cooper, C.B.1
  • 25
    • 15044362349 scopus 로고    scopus 로고
    • Recent developments in inhaled therapy in stable chronic obstructive pulmonary disease
    • Cooper CB, Tashkin DP. 2005. Recent developments in inhaled therapy in stable chronic obstructive pulmonary disease. BMJ, 330:640-44.
    • (2005) BMJ , vol.330 , pp. 640-644
    • Cooper, C.B.1    Tashkin, D.P.2
  • 26
    • 0017816443 scopus 로고
    • The relations between structural changes in small airways and pulmonary function tests
    • Cosio M, Ghezzo H, Hogg JC, et al. 1978. The relations between structural changes in small airways and pulmonary function tests. N Engl J Med, 298:1277-81.
    • (1978) N Engl J Med , vol.298 , pp. 1277-1281
    • Cosio, M.1    Ghezzo, H.2    Hogg, J.C.3
  • 27
    • 0345074173 scopus 로고    scopus 로고
    • Effect of inhaled bronchodilators on inspiratory capacity and dysnoea at rest in COPD
    • Di Marco F, Milic-Emili J, Boveri B, et al. 2003. Effect of inhaled bronchodilators on inspiratory capacity and dysnoea at rest in COPD. Eur Respir J, 21:86-94.
    • (2003) Eur Respir J , vol.21 , pp. 86-94
    • Di Marco, F.1    Milic-Emili, J.2    Boveri, B.3
  • 28
    • 0033883907 scopus 로고    scopus 로고
    • Role of inspiratory capacity on exercise tolerance in COPD patients with and without tidal expiratory flow limitation at rest
    • Diaz O, Villafranca C, Ghezzo H, et al. 2000. Role of inspiratory capacity on exercise tolerance in COPD patients with and without tidal expiratory flow limitation at rest. Eur Respir J, 16:269-75.
    • (2000) Eur Respir J , vol.16 , pp. 269-275
    • Diaz, O.1    Villafranca, C.2    Ghezzo, H.3
  • 29
    • 60249090309 scopus 로고    scopus 로고
    • Respiratory and skeletal muscles in chronic obstructive pulmonary disease
    • Gayan-Ramirez G, Koulouris N, Roca J, et al. 2006. Respiratory and skeletal muscles in chronic obstructive pulmonary disease. Eur Respir Mon, 38:201-23.
    • (2006) Eur Respir Mon , vol.38 , pp. 201-223
    • Gayan-Ramirez, G.1    Koulouris, N.2    Roca, J.3
  • 30
    • 0037092554 scopus 로고    scopus 로고
    • β-agonist intrinsic efficacy: Measurement and clinical significance
    • Hanania NA, Sharafkhaneh A, Barber R, et al. 2002. β-agonist intrinsic efficacy: measurement and clinical significance. Am J Respir Crit Care Med, 165:1353-8.
    • (2002) Am J Respir Crit Care Med , vol.165 , pp. 1353-1358
    • Hanania, N.A.1    Sharafkhaneh, A.2    Barber, R.3
  • 31
    • 4344675455 scopus 로고    scopus 로고
    • Pathophysiology of airflow limitation in chronic obstructive pulmonary disease
    • Hogg JC. 2004. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet, 364:709-21.
    • (2004) Lancet , vol.364 , pp. 709-721
    • Hogg, J.C.1
  • 32
    • 2942720573 scopus 로고    scopus 로고
    • The nature of small airway obstruction in chronic obstructive pulmonary disease
    • Hogg JC, Chu F, Utokaparch S, et al. 2004. The nature of small airway obstruction in chronic obstructive pulmonary disease. N Engl J Med, 350:2645-53.
    • (2004) N Engl J Med , vol.350 , pp. 2645-2653
    • Hogg, J.C.1    Chu, F.2    Utokaparch, S.3
  • 33
    • 0014424329 scopus 로고
    • Site and nature of airways obstruction in chronic obstructive lung disease
    • Hogg JC, Macklem PT, Thurlbeck WM. 1968. Site and nature of airways obstruction in chronic obstructive lung disease. N Engl J Med, 278:1355-60.
    • (1968) N Engl J Med , vol.278 , pp. 1355-1360
    • Hogg, J.C.1    Macklem, P.T.2    Thurlbeck, W.M.3
  • 34
    • 0036303552 scopus 로고    scopus 로고
    • Faster onset of bronchodilation with formoterol than with salmeterol in patients with stable, moderate to severe COPD. Results of a randomized, double-blind clinical study
    • Kottakis J, Della Cioppa G, Creemers J, et al. 2002. Faster onset of bronchodilation with formoterol than with salmeterol in patients with stable, moderate to severe COPD. Results of a randomized, double-blind clinical study. Can Respir J, 9:107-15.
    • (2002) Can Respir J , vol.9 , pp. 107-115
    • Kottakis, J.1    Della Cioppa, G.2    Creemers, J.3
  • 38
    • 0242577942 scopus 로고    scopus 로고
    • Contemporary management of chronic obstructive pulmonary disease
    • Man SFP, McAlister FA, Anthonisen NR, et al. 2003. Contemporary management of chronic obstructive pulmonary disease. JAMA, 290:2313-16.
    • (2003) JAMA , vol.290 , pp. 2313-2316
    • Man, S.F.P.1    McAlister, F.A.2    Anthonisen, N.R.3
  • 39
    • 2942692139 scopus 로고    scopus 로고
    • Effect of salmeterol on respiratory muscle activity during exercise in poorly reversible COPD
    • Man WDC, Mustfa N, Nikoletou D, et al. 2004. Effect of salmeterol on respiratory muscle activity during exercise in poorly reversible COPD. Thorax, 59:471-76.
    • (2004) Thorax , vol.59 , pp. 471-476
    • Man, W.D.C.1    Mustfa, N.2    Nikoletou, D.3
  • 40
    • 26444543237 scopus 로고    scopus 로고
    • An acute bronchodilator test with tiotropium or salmeterol does not allow a subdivision of patients according to responses
    • Matera MG, Sanduzzi A, Ponticiello A, et al. 2005. An acute bronchodilator test with tiotropium or salmeterol does not allow a subdivision of patients according to responses. Respiration, 72:466-70.
    • (2005) Respiration , vol.72 , pp. 466-470
    • Matera, M.G.1    Sanduzzi, A.2    Ponticiello, A.3
  • 41
    • 0034705111 scopus 로고    scopus 로고
    • Chronic β-adrenergic stimulation induces myocardial proinflammatory cytokine expression
    • Murray DR, Prabhu SD, Chandrasekar B. 2000. Chronic β-adrenergic stimulation induces myocardial proinflammatory cytokine expression. Circulation, 101:2338-41.
    • (2000) Circulation , vol.101 , pp. 2338-2341
    • Murray, D.R.1    Prabhu, S.D.2    Chandrasekar, B.3
  • 42
    • 0035985520 scopus 로고    scopus 로고
    • Chronically inhaled salmeterol improves pulmonary function in heart failure
    • Ng TM, Munger MA, Lombatri WL, et al. 2002. Chronically inhaled salmeterol improves pulmonary function in heart failure. J Cardiovasc Pharmacol, 40:140-45.
    • (2002) J Cardiovasc Pharmacol , vol.40 , pp. 140-145
    • Ng, T.M.1    Munger, M.A.2    Lombatri, W.L.3
  • 43
    • 0035446990 scopus 로고    scopus 로고
    • Dynamic hyperinflaction and exercise intolerance in chronic obstructive pulmonary disease
    • O'Donnell DE, Lam M, Webb KA. 2001. Dynamic hyperinflaction and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 164:770-77.
    • (2001) Am J Respir Crit Care Med , vol.164 , pp. 770-777
    • O'Donnell, D.E.1    Lam, M.2    Webb, K.A.3
  • 44
    • 3543055330 scopus 로고    scopus 로고
    • Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease
    • O'Donnell DE, Voduc N, Fitzpatrick M, et al. 2004. Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease. Eur Respir J, 24:86-94.
    • (2004) Eur Respir J , vol.24 , pp. 86-94
    • O'Donnell, D.E.1    Voduc, N.2    Fitzpatrick, M.3
  • 45
    • 0035035768 scopus 로고    scopus 로고
    • Global strategy for the diagnosis, management and prevention of chronich obstructive pulmonary disease
    • Pauwels RA, Buist AS, Calverley PMA, et al. 2001. Global strategy for the diagnosis, management and prevention of chronich obstructive pulmonary disease. Am J Respir Crit Care Med, 163:1256-76.
    • (2001) Am J Respir Crit Care Med , vol.163 , pp. 1256-1276
    • Pauwels, R.A.1    Buist, A.S.2    Calverley, P.M.A.3
  • 47
    • 38449115415 scopus 로고    scopus 로고
    • Diagnosis and management of stable chronic obstructive pulmonary disease: A clinical practice guideline from the American College of Physicians
    • Qaseem A, Snow V, Shekelle P, et al. 2007. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline from the American College of Physicians. Ann Inter Med, 147:633-38.
    • (2007) Ann Inter Med , vol.147 , pp. 633-638
    • Qaseem, A.1    Snow, V.2    Shekelle, P.3
  • 48
    • 33847161293 scopus 로고    scopus 로고
    • Treating COPD - The TORCH Trial, P values, and the Dodo
    • Rabe KF. 2007. Treating COPD - The TORCH Trial, P values, and the Dodo. N Engl J Med, 356:851-54.
    • (2007) N Engl J Med , vol.356 , pp. 851-854
    • Rabe, K.F.1
  • 49
    • 34548660457 scopus 로고    scopus 로고
    • Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: GOLD executive summary
    • Rabe KF, Hurd SS, Anzueto A, et al. 2007. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med, 176:532-55.
    • (2007) Am J Respir Crit Care Med , vol.176 , pp. 532-555
    • Rabe, K.F.1    Hurd, S.S.2    Anzueto, A.3
  • 50
    • 0038467559 scopus 로고    scopus 로고
    • Cardiovascular safety of salmeterol in patients with COPD
    • Reisner C, Funck-Brentano C, Fischer T, et al. 2003. Cardiovascular safety of salmeterol in patients with COPD. Chest, 123:1817-24.
    • (2003) Chest , vol.123 , pp. 1817-1824
    • Reisner, C.1    Funck-Brentano, C.2    Fischer, T.3
  • 51
    • 73549083024 scopus 로고    scopus 로고
    • Bronchodilators in chronic obstructive pulmonary disease
    • Rennard SI, Calverley PMA. 2006. Bronchodilators in chronic obstructive pulmonary disease. Eur Respir Mon, 38:266-80.
    • (2006) Eur Respir Mon , vol.38 , pp. 266-280
    • Rennard, S.I.1    Calverley, P.M.A.2
  • 52
    • 10644240946 scopus 로고    scopus 로고
    • Mucociliary dysfunction in COPD: Effect of current pharmacotherapeutic options
    • Rogers DF. 2005. Mucociliary dysfunction in COPD: effect of current pharmacotherapeutic options. Pulm Pharmacol Ther, 18:1-8.
    • (2005) Pulm Pharmacol Ther , vol.18 , pp. 1-8
    • Rogers, D.F.1
  • 53
    • 0036206172 scopus 로고    scopus 로고
    • Comparison of the efficacy, tolerability and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD
    • Rossi A, Kristufek P, Levine BE, et al. 2002. Comparison of the efficacy, tolerability and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest, 121:1058-69.
    • (2002) Chest , vol.121 , pp. 1058-1069
    • Rossi, A.1    Kristufek, P.2    Levine, B.E.3
  • 54
    • 0000313603 scopus 로고
    • Dynamic Hyperinflation
    • Marini JJ and Roussos C eds, Berlin: Springer-Verlag. p
    • Rossi A, Polese G, Brandi G. 1991. Dynamic Hyperinflation. In: Marini JJ and Roussos C (eds). Ventilatory Failure. Berlin: Springer-Verlag. p 199-218.
    • (1991) Ventilatory Failure , pp. 199-218
    • Rossi, A.1    Polese, G.2    Brandi, G.3
  • 55
    • 0033374914 scopus 로고    scopus 로고
    • Abnormality of left ventricular sympathetic nervous function assessed by (123)I-metaiodobenzylguanidine imaging in patients with COPD
    • Sakamaki F, Satoh T, Nagaya N, et al. 1999. Abnormality of left ventricular sympathetic nervous function assessed by (123)I-metaiodobenzylguanidine imaging in patients with COPD. Chest, 116:1575-81.
    • (1999) Chest , vol.116 , pp. 1575-1581
    • Sakamaki, F.1    Satoh, T.2    Nagaya, N.3
  • 56
    • 33745306721 scopus 로고    scopus 로고
    • Meta-analysis: Effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths
    • Salpeter SR, Buckley NS, Ormiston TM, et al. 2006a. Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths. Ann Inter Med, 144:904-12.
    • (2006) Ann Inter Med , vol.144 , pp. 904-912
    • Salpeter, S.R.1    Buckley, N.S.2    Ormiston, T.M.3
  • 57
    • 33748369326 scopus 로고    scopus 로고
    • Meta-Analysis: Anticholinergic, but not β-agonists, reduce severe exacerbations and respiratory mortality in COPD
    • Salpeter SR, Buckley NS, Salpeter EE. 2006b. Meta-Analysis: Anticholinergic, but not β-agonists, reduce severe exacerbations and respiratory mortality in COPD. J Gen Intern Med, 21:1011-19.
    • (2006) J Gen Intern Med , vol.21 , pp. 1011-1019
    • Salpeter, S.R.1    Buckley, N.S.2    Salpeter, E.E.3
  • 58
    • 2942744546 scopus 로고    scopus 로고
    • Cardiovascular effects of β-agonists in patients with asthma and COPD
    • Salpeter SR, Ormiston TM, Salpeter EE. 2004. Cardiovascular effects of β-agonists in patients with asthma and COPD. Chest, 125:2309-21.
    • (2004) Chest , vol.125 , pp. 2309-2321
    • Salpeter, S.R.1    Ormiston, T.M.2    Salpeter, E.E.3
  • 60
    • 0029156848 scopus 로고
    • Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force
    • Siafakas NM, Vermeire P, Pride NB, et al. 1995. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur Respir J, 8:1398-420.
    • (1995) Eur Respir J , vol.8 , pp. 1398-1420
    • Siafakas, N.M.1    Vermeire, P.2    Pride, N.B.3
  • 61
    • 0242577949 scopus 로고    scopus 로고
    • Contemporary management of chronic obstructive pulmonary disease
    • Sin DD, McAlister FA, Man SFP, et al. 2003. Contemporary management of chronic obstructive pulmonary disease. JAMA, 290:2301-12.
    • (2003) JAMA , vol.290 , pp. 2301-2312
    • Sin, D.D.1    McAlister, F.A.2    Man, S.F.P.3
  • 62
    • 0028913892 scopus 로고
    • The QTc interval, autonomic neuropathy and mortality in hypoxaemic COPD
    • Stewart AG, Waterhouse JC, Howard P. 1995. The QTc interval, autonomic neuropathy and mortality in hypoxaemic COPD. Respir Med, 89:79-84.
    • (1995) Respir Med , vol.89 , pp. 79-84
    • Stewart, A.G.1    Waterhouse, J.C.2    Howard, P.3
  • 63
    • 2942729608 scopus 로고    scopus 로고
    • Management of chronic obstructive pulmonary disease
    • Sutherland ER, Cherniack RM. 2004. Management of chronic obstructive pulmonary disease. N Engl J Med, 350:2689-97.
    • (2004) N Engl J Med , vol.350 , pp. 2689-2697
    • Sutherland, E.R.1    Cherniack, R.M.2
  • 64
    • 0037246566 scopus 로고    scopus 로고
    • Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease
    • Szafranski W, Cukier A, Ramirez R, et al. 2003. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J, 21:74-81.
    • (2003) Eur Respir J , vol.21 , pp. 74-81
    • Szafranski, W.1    Cukier, A.2    Ramirez, R.3
  • 65
    • 1642493871 scopus 로고    scopus 로고
    • The role of long-acting bronchodilators in the management of stable COPD
    • Tashkin DP, Cooper GB. 2004. The role of long-acting bronchodilators in the management of stable COPD. Chest, 125:249-59.
    • (2004) Chest , vol.125 , pp. 249-259
    • Tashkin, D.P.1    Cooper, G.B.2
  • 66
    • 0037502770 scopus 로고    scopus 로고
    • 2-adrenoceptor agonists or tiotropium bromide for patients with COPD: Is combination therapy justified?
    • 2-adrenoceptor agonists or tiotropium bromide for patients with COPD: is combination therapy justified? Curr Opin Pharmacol, 3:270-6.
    • (2003) Curr Opin Pharmacol , vol.3 , pp. 270-276
    • Tennant, R.C.1    Erin, E.M.2    Barnes, P.J.3
  • 67
    • 4344710679 scopus 로고    scopus 로고
    • The TORCH (Towards a Revolution in COPD Health) survival study protocol
    • The TORCH Study Group
    • The TORCH Study Group. 2004. The TORCH (Towards a Revolution in COPD Health) survival study protocol. Eur Respir J, 24:206-10.
    • (2004) Eur Respir J , vol.24 , pp. 206-210
  • 68
    • 23144457098 scopus 로고    scopus 로고
    • Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD
    • Van Noord JA, Aumann JL, Janssens E, et al. 2005. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J, 26:214-22.
    • (2005) Eur Respir J , vol.26 , pp. 214-222
    • Van Noord, J.A.1    Aumann, J.L.2    Janssens, E.3
  • 69
    • 33645116728 scopus 로고    scopus 로고
    • Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD
    • Van Noord JA, Aumann JL, Janssens E, et al. 2006. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest, 129:509-17.
    • (2006) Chest , vol.129 , pp. 509-517
    • Van Noord, J.A.1    Aumann, J.L.2    Janssens, E.3
  • 70
    • 0018092991 scopus 로고    scopus 로고
    • 19 78. Ventilation-perfusion inequality in asymptomatic asthma
    • Wagner PD, Dantzker DR, Lacovoni VE, et al. 19 78. Ventilation-perfusion inequality in asymptomatic asthma. Am Rev Respir Dis, 118:511-24.
    • Am Rev Respir Dis , vol.118 , pp. 511-524
    • Wagner, P.D.1    Dantzker, D.R.2    Lacovoni, V.E.3
  • 71
    • 0033995550 scopus 로고    scopus 로고
    • β-Agonistic bronchodilators: Comparison of dose/response in working rat hearts
    • Zimmer G, Dahinten A, Fitzner A, et al. 2000. β-Agonistic bronchodilators: comparison of dose/response in working rat hearts. Chest, 117:519-29.
    • (2000) Chest , vol.117 , pp. 519-529
    • Zimmer, G.1    Dahinten, A.2    Fitzner, A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.